Forty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
|
|
- Adrian Baldwin
- 5 years ago
- Views:
Transcription
1 SAFE USE OF ANTIDEPRESSANTS IN THE BLACK BOX ERA Adelaide Robb, MD Associate Professor, Psychiatry and Pediatrics Source DISCLOSURE Advisory Board Speaker s Bureau Bristol Myers Squibb Epocrates Research Contract Royalties Stock Janssen Forest Glaxo Smith Kline McNeil Merck/Scherring Lilly Lundbeck Pfizer Otsuka Shinogi Supernus NICHD CHADD OVERVIEW The SSRIs and approvals FDA rules and changes Definitions of black box and medication guide Data leading up to the antidepressant black box FDA published articles on suicide rates adults and kids The antidepressant black box The information from GPRD/ Jick article and Bridges What to do with your patients
2 Selective Serotonin Reuptake Inhibitors Common Side Pharmocologic Special Drug name Initial dose Increment Maximum Half Life Effects Considerations Considerations nausea, vomiting, inhibits CYP2D6, little Fluoxetine anxiety,sexual long time to discontinuation Prozac 10-20mg 10-20mg 80mg 4-6days dysfunction therapeutic syndrome nausea,sexual Sertaline dysfunction, mild inhibition clinical effect 3-6 Zoloft 25-50mg mg 200mg 26hrs insomnia CYP2D6 weeks sedating, Incr. nausea,dry weight, Paroxetine mouth,sex more anticholinergic syndrome discontinuation Paxil 10-20mg 10mg 60mg hrs dysfunction higher Incr. GI poss discontinuation Fluvoxamine less sexual potent inhibition risk, drug Luvox 25-50mg 25-50mg 300mg hrs dysfunction p4502d6 interactions nausea, dry mouth, somnolence, concern of slight Citalopram insomnia,sexual less p4502d6 increase Celexa 10-20mg 10mg 60mg 35 hr dysfunction inhibition overdose risk nausea,delayed ejaculation, insomnia, somnolence, single isomer of Escitalopram diarrhea, citalopram, no Lexapro 5-10mg 5mg 20mg 27-32hr sweating clear advantage no generic FDA HISTORY Division of Chemistry Investigated adulteration of questionable food additives and drugs of the time Bureau of Chemistry the Food and Drugs Act Prohibited interstate transport of drugs Drugs must meet USP and NF standards misbranded Food or drug label could not be false or misleading 1937-Sulfanilamide experience diethylene glycol for pediatrics, died of antifreeze poisoning FDA HISTORY II 1938-Food Drug and Cosmetic Act FD&C Act need a prescription, must demonstrate SAFETY 1951 Durham Humphrey Amendment OTC v RX labeling FDA authority to classify 1957 Thalidomide Europe, 1960 NDA in US; 1962 Dr. Kelsey says not enough info NDA withdrawn 1962 Kefauver-Harris Amendments, drugs need to be safe and EFFECTIVE; need to have efficacy of all drugs FDA approved since 1938; trials need informed consent
3 FDA HISTORY III 1965-Drug Abuse Control amendments passed 1968-Drug Abuse Control amendments and other laws were compiled to form DEA 1997 FDAMA-FDA modernization act, prescription drug users fee act (PDUFA); pay registration fee have priority drugs 1997 Pediatric Rule all drugs must be tested in kids as part of package-later struck down by courts 2002 Best Pharmaceutical Act for Children mo extra patent if do FDA required studies FDA HISTORY IV-CHILDREN 2007 BPCA and PREA reauthorized 2003 Pediatric Research Equity Act PREA Established the Pediatric Advisory Committee The FDA Stick Mandates pediatric studies of drugs by drug companies Failure to comply may render drugs misbranded Retroactive to drugs approved since April 1, 1999 Studies must show safety, efficacy and appropriate dosing BPAC and PREA sunset 2012 unless reenacted by Congress DEFINITIONS Black box-the highest level of warning before a drug is removed from the market Stronger than bolded warning Medication guide-a specialized handout required by the manufacturer to be dispensed with every prescription for the drug, usually but not always given out as part of a black box program Not all black boxed drugs have med guides and vice versa
4 FDA ADVISORY COMMITTEE Give independent advice to the FDA Committee decisions are NOT binding Committee members are NOT full time FDA employees Membership by law must be fairly balanced and composed of: Recognized clinical experts in field of study Researchers Academic professors Lay consumer Industry representative (non voting) General public, can address any advisory committee during a 60 minute open forum discussion prior to committee deliberations. SUICIDE RATES BY AGE/100,000 Age Range Rate 5-9 years years years years SUICIDE BY AGE, RACE & GENDER Population years years EA males AA males EA females AA females
5 FDA DATA KIDS I Hammad et al Arch Gen Psychiatry Mar;63(3):332-9 Investigate the relationship between antidepressant drugs and suicidality in pediatric patients participating in randomized, placebo-controlled trials 23 trials conducted in 9 drug companysupported programs evaluating the effectiveness of antidepressants in pediatric patients and 1 multi-center trial (TADS) that evaluated fluoxetine hydrochloride FDA DATA KIDS II All placebo-controlled trials submitted to the FDA 4582 patients in 24 trials 16 MDD, 4 OCD, 2 GAD,1 ADHD, & 1 SAD Only 20 trials were included in the risk ratio analysis of suicidality because 4 trials had no events in the drug or placebo groups Meta-analysis was conducted to obtain overall suicidality risk estimates for each drug individually, for SSRI's in depression trials as a group, and for all 20 trials combined FDA DATA KIDS III No completed suicides in any of these trials TADS was the only individual trial to show a statistically significant risk ratio (4.62; 95% confidence interval [CI], Overall risk ratio for SSRI s in MDD trials was 1.66 (95% CI, ) and for all drugs across all indications was 1.95 (95% CI, ). The overall risk difference for all drugs across all indications was 0.02 (95% CI, )
6 FDA DATA KIDS IV Use of antidepressant drugs in pediatric patients is associated with a modestly increased risk of suicidality over placebo Highest was 1.95 risk ratio This data led to the black box warning saying 2% suicidality on placebo and 4% on medication Still way below suicide attempt rates for MDD in same age group and 29% ideation rate at entry into TADS ANTIDEPRESSANT FDA HEARINGS Child and Adult psychiatry decidedly absent at first and second hearings Many plaintiff s lawyers, scientologists, and others came to complain Very few child psychiatrists and even fewer adult psychiatrists came No pediatric support One patient who benefited came We lost by numbers alone FDA BLACK BOX WARNING Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents and young adults in short term studies of depression and other psychiatric disorders Short term studies did not show and increase in suicidality with antidepressants compared to placebo in adults beyond age 24 Depression and other psychiatric disorders are themselves associated with increases in the risk of suicide All patients starting antidepressants should be monitored appropriately and observed closely Families and caregivers should discuss with the HCP right away any observations of worsening depression symptoms, suicidal thinking and behavior, or unusual changes in behavior
7 FDA BB RECOMMENDATIONS If left untreated, depression can worsen and make life difficult for your adolescent and the entire family. Depression in adolescents is associated with:* High risk of completed and attempted suicide Significant morbidity Other psychiatric disorders Adult depression Disruptive behavior Substance abuse Eating disorders Withdrawal from peers School absenteeism and decreased performance Disruption of social functioning (work, school, relationships) Emotional distress Early pregnancy Physical illness *The effect of Lexapro on these outcomes has not been studied. How can treatment help? The appropriate treatment plan for your adolescent is important because it may help your adolescent: Feel better Improve social and family relationships Improve performance at school Enjoy activities and hobbies more Get greater enjoyment out of life CONTROVERSY OVER SUICIDE Paxil withdrawn due to increased suicidal ideation in active treatment arm compared with placebo arm in pediatric MDD trials 3.2% v 1.5% FDA warning do not use in pediatric MDD Effexor in GAD and MDD increased anger and increase suicidal ideation of 2% v 0% in placebo arm Company warning do not use pediatric MDD FDA hearings 2004 ANTIDEPRESSANTS AND RISK OF SUICIDAL BEHAVIORS Jick et al JAMA 21 July 04, used GPRD data base of GP s in England from and looked at year olds who had first start of antidepressants Paroxetine, Fluoxetine, Amitriptylene and Dothiepin 159,810 users, must use only 1 and within 90 days of index date Non-fatal suicidal behavior 555 cases and 2062 age, sex matched controls Relative risk to Doth of non-fatal suicidal behavior 0.83 Ami, 1.16 Flu, 1.29 Par
8 JICK II RR of non-fatal suicidal behavior days 1to 9 c/w >90 d 4.07, 10-29d 2.88, 30-89d 1.53 RR of non-fatal suicidal behavior who stopped antidepressants 0.71 c/w >90d on meds and 0.91 c/w d on meds i.e. no increase in RR with cessation of treatment No difference in RR by age including in yo, but more attempters female 65% and 12.3% 10-19yo c/w 31.9% 20-29yo and 24.1% 30-39yo JICK III COMPLETED SUICIDE 17 completed suicides who received 1 study drug in 90d with no prior documented suicidal behavior (prior suicide attempt known to confer 18 fold RR of repeat attempt or suicide) or history of multiple AD drugs (2.8 fold RR of SA or S) 76% male NONE 10-19yo; 53% 20-39yo, 47% 40-69yo, 3 Ami, 7 Dot, 4 Flu, 3 Par Days 1to 9 38 fold RR c/w 90d, d 5.1RR, RR Same time period yo suicides in GPRD data base none had received an antidepressant drug SUICIDE TRENDS AFTER BLACK BOX Letter by JA Bridge et al JAMA (9) Steady decline 10 years in youth <20 In increased by 18% largest single change in 15 years national fatal injury data Risk of suicide per 100,000 person years Used trend line from to estimate 2004 and 2005 data Did observed number of deaths minus expected deaths to determine excess death Overall suicide decreased 5.3% from 2004 to 2005 Actual rate still above expected by gender and age excess suicides, excess suicides
9 META-ANALYSIS AD AND SI/SA Bridge JAMA April pubmed, FDA, MHRA clinical trials <19yo % v 2% risk 27 trials 15 MDD, 6 OCD, 6 nonocd Efficacy responder status drug>pbo NNT MDD 10, 6 OCD, non-ocd 3 NNH 143 for AD MDD, OCD, non-ocd Outcomes change from baseline in scale Risk outcome SI/SA using Columbia scheme CGI/CDRS-R, CYBOCS, non-ocd CGI and PARS
10 META-ANALYSIS AD AND SI/SA MDD 13 trials 2910 participants rates of response 61% ad v 50% pbo, pooled risk difference 11% NNT 10 Pooled suicide rates AD 3% Pbo 2% Pooled risk difference 1% NNH 112 OCD 6 trials 705 participants rates of response 52% ad v 32% pbo, pooled risk difference 20% NNT 6 Pooled suicide rates AD 1% Pbo 0.3% Pooled risk difference 0.5% NNH 200 META-ANALYSIS AD AND SI/SA Non-OCD 6 trials 1136 participants rates of response 69% ad v 39% pbo, pooled risk difference 37% NNT 3 Pooled suicide rates AD 1% Pbo 0.3% Pooled risk difference 0.7% NNH MDD age split adolescents > children Flu pooled risk response kids 21% teens 2% FLU ES higher with more severe.69 v.39 MDD ES inversely proportional to duration OCD teen child pooled risk no effect of PBO run in 3 non-ocd pooled risk 46% teens v 29% No evidence of publication bias CHANGES SINCE BLACK BOX In Netherlands from 2003 to 2005 the rate of antidepressant prescriptions to patients under 18 fell 22% From 2003 to 2005 suicides in patients under 18 rose 50% from 34 suicides to 51 suicides-presented at ACNP CDC adolescent suicide rates rose in 2004-first time in a decade when antidepressant rates dropped Autopsy study of adolescent suicides-few had antidepressants in their system
11 CHANGES SINCE BLACK BOX II Study of suicide attempts by county in US notes those with highest antidepressant use have lowest suicide rates AJP 2006 FDA meta-analysis of adult rates shows 2 fold increase in ideation/attempt of those <25 years old on drug compared with placebo WHAT WE LEARNED If we don t fight others decide for us No one else will stand up for treatment for our patients Stigma is bad enough If patients worry meds cause death, people will not get help Enlist the pediatricians, their numbers are bigger, and they will lobby if they think it helps their patients WHAT TO DO WITH PEDIATRIC PATIENTS If a new pediatric patient needs an antidepressant, you must explain risks and benefits including suicidal ideation and attempts Offer therapy first if that is family s preference Document suicide assessment in the chart In psychiatry only 2 drugs have ever been shown to lower suicide risk, lithium in bipolar and clozapine for schizophrenia
12 WHAT TO DO WITH PEDIATRIC PATIENTS Our goal for treatment with medications is to return to baseline functioning, not to lower suicide risk Remember based on Jick article period of highest risk is during first 2 weeks You may need to advocate for extra visits with insurance company so your pediatric patients have better care and coverage Ongoing assessment and education is necessary QUESTIONS?
Forty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
Recognizing OCD and Anxiety Disorders in Children Adelaide Robb, MD Associate Professor Psychiatry and Pediatrics Source Advisory Board Disclosure Speaker s Bureau Bristol Myers Squibb Epocrates Research
More informationForty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
Adelaide Robb, MD Associate Professor Psychiatry and Pediatrics Source Advisory Board Disclosure Speaker s Bureau Bristol Myers Squibb Yes Yes Yes Epocrates Research Contract Royalties Yes Stock Janssen
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry
More informationCITIZENS PETITION TO FOOD AND DRUG ADMINISTRATION. Division of Dockets Management Food and Drug Administration Room Fishers Lane
CITIZENS PETITION TO FOOD AND DRUG ADMINISTRATION Division of Dockets Management Food and Drug Administration Room 1061 5630 Fishers Lane Rockville, MD 20852 ) ALLIANCE FOR NATURAL HEALTH USA ) 1350 Connecticut
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationAverage dose zoloft for ocd and anxiety
Average dose zoloft for ocd and anxiety Gogamz Menu DESCRIPTION. Selective serotonin reuptake inhibitor (SSRI). Approved for depression, OCD, panic disorder, PTSD, premenstrual-dysphoric disorder (PMDD),
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationExplain to patients and families the meaning and ramifications of FDA warnings regarding antidepressants. Appropriately monitor patients on
Antidepressants in Children and Adolescents: The Good, The Bad & The Ugly Raymond C. Love, Pharm.D., BCPP, FASHP Associate Dean and Professor, Pharmacy Practice & Science University of Maryland, School
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Child and Adolescent Psychiatry Residency Training, Massachusetts
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationPediatrics Grand Rounds 5 March University of Texas Health Science Center at San Antonio I-1
Diagnosis and Treatment of Depression in Children and Adolescents Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The Disclosures
More informationManagement Of Depression And Anxiety
Management Of Depression And Anxiety CME Financial Disclosure Statement I, or an immediate family member including spouse/partner, have at present and/or have had within the last 12 months, or anticipate
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationOptimistic News and Practical Tools. The Role of Primary Care in Screening and Managing Teen Depression
Optimistic News and Practical Tools The Role of Primary Care in Screening and Managing Teen Depression Meg Durbin, MD Palo Alto Medical Foundation DurbinM@pamf.org Educational Objectives Learn: steps for
More informationDepression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms
Depression and Anxiety By Christopher Okiishi, MD Spring 2016 What is Depression? Not just being sad A syndrome of symptoms Depressed mood Sleep disturbance Decreased interest in usual activities (anhedonia)
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationDisclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017
Psychopharmacology of Pediatric Anxiety and Depression Susan Sharp, DO Clinical Assistant Professor of Child and Adolescent Psychiatry Kansas University Medical Center The Children's Mercy Hospital, 2017
More informationClinical Policy: Clomipramine (Anafranil) Reference Number: HIM.PA.149 Effective Date: Last Review Date: 05.18
Clinical Policy: (Anafranil) Reference Number: HIM.PA.149 Effective Date: 03.13.18 Last Review Date: 05.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationThe Adolescent with ADHD: Managing Transition
The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli
More informationClinical Policy: Levomilnacipran (Fetzima) Reference Number: HIM.PA.125 Effective Date: Last Review Date: 11.18
Clinical Policy: (Fetzima) Reference Number: HIM.PA.125 Effective Date: 12.01.17 Last Review Date: 11.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other BUPROPION HCL WELLBUTRIN, 01653 WELLBUTRIN SR, WELLBUTRIN XL BUPROPION HBR APLENZIN 17050 16996 26198 CITALOPRAM CELEXA 10321 GPID 16344 HYDROBROMIDE DESVENLAFAXINE
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationThat man is truly good who knows his own dark places. Beowulf (8 th -11 th century)
That man is truly good who knows his own dark places. Beowulf (8 th -11 th century) SSRIs 1 (enlarged slide appended) Reference: British Medical Journal, 13 October 2007, Volume 335 2 Learning Objectives
More information2/23/18. Age of Anxiety: Transforming Qualms into Calm. Disclosures. Objectives. I have nothing to disclose
Age of Anxiety: Transforming Qualms into Calm Rosa Kim, MD Assistant Professor and Attending Child Psychiatrist Medical College of Wisconsin and Children s Hospital of Wisconsin Disclosures I have nothing
More informationUPDATE April 5, 2006 BRIEFING DOCUMENT. Paroxetine Adult Suicidality Analysis: Major Depressive Disorder and Non- Major Depressive Disorder
UPDATE April 5, 2006 BRIEFING DOCUMENT Paroxetine Adult Suicidality Analysis: Major Depressive Disorder and Non- Major Depressive Disorder 1. Introduction Selective serotonin reuptake inhibitors (SSRIs)
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationForty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
Child Psychiatry Case Studies Adelaide Robb, MD Associate Professor Psychiatry and Pediatrics Source Advisory Board Disclosure Speaker s Bureau Bristol Myers Squibb Epocrates Research Contract Royalties
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationRealities of Depression in Primary Care Setting
Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have
More informationSelective Serotonin Reuptake Inhibitor (SSRI) Step Therapy Program
Selective Serotonin Reuptake Inhibitor (SSRI) Step Therapy Program Policy Number: 5.01.587 Last Review: 7/2018 Origination: 7/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas
More informationTaking Care: Child and Youth Mental Health TREATMENT OPTIONS
Taking Care: Child and Youth Mental Health TREATMENT OPTIONS Open Learning Agency 2004 TREATMENT OPTIONS With appropriate treatment, more than 80% of people with depression get full relief from their symptoms
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationMedications in Autism: What We Know and Don't Know
Medications in Autism: What We Know and Don't Know Jeremy Veenstra-VanderWeele, M.D. Mortimer D. Sackler, M.D., Associate Professor Center for Autism and the Developing Brain Sackler Institute for Developmental
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationANTI-DEPRESSANT MEDICATIONS
ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationGeneralized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6
Generalized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control.
More informationDepression & Suicide 7/11/2017 DISCLOSURES. DSM 5 Depressive Disorders. Objectives
DISCLOSURES Depression & Suicide July 19, 2017 GenaLynne C. Mooneyham, MD, MS Pediatrics/Psychiatry/Child & Adolescent Psychiatry No financial disclosures There may be discussion of off label medication
More informationAn Industry- Biased Record
SSRI Use In Children: An Industry- Biased Record February 2004 By Merrill Goozner and Jeff DelViscio Tel: (202) 332-9110 Fax: (202) 265-4954 www.cspinet.org Suite 300 1875 Connecticut Avenue, NW Washington,
More informationFROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY
13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationZoloft (sertraline) FDA ALERT [05/2007] Suicidal Thoughts or Actions in Children and Adults
Zoloft (sertraline) FDA Alerts FDA ALERT [05/2007] Suicidal Thoughts or Actions in Children and Adults Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality)
More informationOverview. Part II: Part I: Screening for Depression and Anxiety Risk Assessment Diagnosis of Depressive Disorders
1 Learning Objectives 1. Providers will become familiar with methods of screening for depression and anxiety. 2. Providers will become more comfortable with diagnosis and management of these common pediatric
More informationlexapro 8 Lexapro and cold symptoms Lexapro without weight gain, methadone zoloft and lexapro. 9 Is lexapro like zoloft
How long does take to wear off, help you to sleep overtime, dosage for ocd treatment, withdrawal cold sweats, social anxiety dosage. Lexapro dose for ocd, can't think straight, pros and cons of the depression
More informationAntidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder
updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trintellix) Reference Number: CP.PMN.65 Effective Date: 05.01.15 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy
More informationNDA /SE5-030/031 (tablets) NDA /SE5-021/022 (oral solution) (This overview should be filed with the submission.
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: February 17, 2009 FROM: TO: SUBJECT: Ni A. Khin,
More informationAbilify (aripiprazole)
Abilify (aripiprazole) FDA ALERT [04/2005] Abilify is a type of medicine called an atypical antipsychotic. FDA has found that older patients treated with atypical antipsychotics for dementia had a higher
More informationMar 6, The most effective medications are described in the next section. Selective serotonin reuptake inhibitors (SSRIs) SSRIs are a highly
Mar 6, 2017. The most effective medications are described in the next section. Selective serotonin reuptake inhibitors (SSRIs) SSRIs are a highly effective treatment for the symptoms of PMS and PMDD. The
More informationMEDICATION GUIDE FLUOXETINE CAPSULES USP
MEDICATION GUIDE FLUOXETINE CAPSULES USP Read the Medication Guide that comes with fluoxetine capsules USP before you start taking them and each time you get a refill. There may be new information. This
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationWomen, Mental Health, and HIV
Women, Mental Health, and HIV Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What is Mental Health? Refers to emotional, psychological, social
More informationfor anxious and avoidant behaviors.
Summary of the Literature on the Treatment of Anxiety Disorders in Children and Adolescents Sucheta D. Connolly, M.D.* Non-OCD anxiety disorders in youth are common and disabling, with 12-month prevalence
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationClinical Policy: Vilazodone (Viibryd) Reference Number: CP.PMN.145 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Viibryd) Reference Number: CP.PMN.145 Effective Date: 08.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for
More information5/12/11. Educational Objectives. Goals
Educational Objectives Learn: steps for initial depression screening and management in primary care when to refer to mental health providers tools for providers and patients principles of collaborative
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationAndrew D. Mosholder, M.D., M.P.H., Epidemiologist. Mark Avigan, M.D., Director Division of Drug Risk Evaluation, HFD-430
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH PID# D030341 DATE: February 18, 2004 FROM: THROUGH:
More informationTreating Childhood Depression in Pediatrics. Martha U. Barnard, Ph.D. University of Kansas Medical Center Pediatrics/Behavioral Sciences
Treating Childhood Depression in Pediatrics Martha U. Barnard, Ph.D. University of Kansas Medical Center Pediatrics/Behavioral Sciences Objectives The learner will: Describe the signs and symptoms of childhood
More informationDemand for Publication of Information Related to Post-Marketing Clinical Trials on Children and Adolescents Using the Antidepressant Paxil
July 16, 2009 GlaxoSmithKline Mr. Marc Dunoyer, President Mr. Yoichi Masuzoe, Health Minister Yakugai Ombudsperson Medwatcher Japan Toshihiro Suzuki, Representative AM Bldg. 4th Floor, 1-14-4 Shinjuku,
More informationPsychiatric Medications. Positive and negative effects in the classroom
Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children
More informationWARNING LETTER TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE John Lechleiter, Ph.D. President & Chief Executive Officer Eli Lilly
More informationLisa Goldstein, MD Child and Adolescent and Adult Psychiatrist
Lisa Goldstein, MD Child and Adolescent and Adult Psychiatrist Past President, Pennsylvania Branch of the International Dyslexia Association drlisa@lisagoldsteinmd.com April 2018 No disclosures, No conflicts.
More informationHDSA welcomes you to Caregiver s Corner. Funded by an educational grant from
HDSA welcomes you to Caregiver s Corner Funded by an educational grant from Caregiver s Corner Webinar, DATE Managing Psychiatric Symptoms Peg Nopoulos, M.D. Professor of Psychiatry, Neurology, and Pediatrics
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationMedication Guide Escitalopram Tablets (ES-sye-TAL-oh-pram)
Medication Guide Escitalopram Tablets (ES-sye-TAL-oh-pram) Read the Medication Guide that comes with escitalopram tablets before you start taking it and each time you get a refill. There may be new information.
More informationTreatment of Anxiety and Mood Disorders. John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY
Treatment of Anxiety and Mood Disorders John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY Disclosure: John T. Walkup, MD Consultant Advisory Board
More informationResident Rotation: Collaborative Care Consultation Psychiatry
Resident Rotation: Collaborative Care Consultation Psychiatry Anna Ratzliff, MD, PhD Ramanpreet Toor, MD James Basinski, MD With contributions from: Jürgen Unützer, MD, MPH, MA Jennifer Sexton, MD, Catherine
More informationAntidepressants Choosing the Right One
Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg
More informationMeta Analysis for Safety: Context and Examples at US FDA
Meta Analysis for Safety: Context and Examples at US FDA Mark Levenson, Ph.D. Division of Biometrics 7 Office of Biostatistics Office of Translational Sciences Center for Drug Evaluation and Research U.S.
More informationMajor depressive disorder (MDD) is the most prevalent. Clinical Guidelines
Clinical Guidelines Annals of Internal Medicine Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians Gerald Gartlehner, MD, MPH;
More informationCELEXA (CITALOPRAM) UTILIZATION AND DOSING MANAGEMENT
BACKGROUND CELEXA (CITALOPRAM) UTILIZATION AND DOSING MANAGEMENT In May 2007, the FDA issued a notice that the agency was updating the black box warning for antidepressants to include warnings about increased
More informationWellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)
Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);
More informationPharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests
Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) University of Texas Health Science Center San Antonio Pharmacotherapy Education and Research Center (PERC) 7703 Floyd Curl Drive - MSC 6220 San
More informationPUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH. DATE: January 5, 2004
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: January 5, 2004 FROM: SUBJECT: TO: Thomas P.
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationDepression and Anxiety in
Depression and Anxiety in Pediatrics: A Primary Provider Focus JOSEPH BECKER DO FAAP SPRING 2017 NJSSNA Disclosures No financial disclosures I am a Pediatrician not a Psychiatrist I am married to a nurse
More informationMirtazapine GENERAL INFORMATION. 15-mg, 30-mg, and 40-mg orally disintegrating tablets (SolTab) Available in generic
Mirtazapine Generic name Available brands Available strengths and formulations Available in generic Mirtazapine Remeron, Remeron SolTab 7.5-mg, 15-mg, 30-mg, and 45-mg tablets 15-mg, 30-mg, and 40-mg orally
More informationMore Than Just Moody Blaise Aguirre, MD Child and Adolescent Psychiatrist McLean Hospital Assistant Professor of Psychiatry Harvard Medical School
More Than Just Moody Blaise Aguirre, MD Child and Adolescent Psychiatrist McLean Hospital Assistant Professor of Psychiatry Harvard Medical School Keep in Mind In the U.S., approximately 10-15% of children/adolescents
More informationPSYCHIATRY INTAKE FORM
Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.
More informationAntidepressant does not relieve repetitive behaviors
NEWS Antidepressant does not relieve repetitive behaviors BY KELLY RAE CHI 16 JUNE 2009 1 / 5 Bitter pill: Negative results from clinical trials of two antidepressants, Celexa and Prozac, challenge the
More informationCLINICAL REVIEW. Selective Serotonin Reuptake Inhibitor (SSRI) Forest Laboratories, Inc. Tablets (5 mg, 10 mg, and 20 mg) and Oral Solution (5 mg/ml)
CLINICAL REVIEW Application Type /Submission #: Submission Code NDA 21-323/S-30 (tablets) (b) (4) (oral solution) SE5 Letter Date 5/22/08 Stamp Date 5/23/08 PDUFA Goal Date 3/23/09 Reviewer Name Review
More informationY. W. Francis Lam, Pharm.D. FCCP University of North Texas Health Science Center Grand Round Rx to OTC Switch: Potentials, Challenges, and Initiatives
1 Rx to OTC Switch Potentials, Challenges, and Initiatives Y. W. Francis Lam, Pharm.D., FCCP Professor of Pharmacology lamf@uthscsa.edu, 7-8355 Educational Goal Attendees will have an overall understanding
More informationDrugs for Emotional and Mood Disorders Chapter 16
Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,
More informationAnxiety disorders are remarkably common among pediatric
Web audio at CurrentPsychiatry.com Dr. Strawn: Predictors of outcome and multimodal treatment for pediatric anxiety An evidence-based approach to treating pediatric anxiety disorders Research supports
More informationThe Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability
The Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability Danielle Adams Principal Clinical Pharmacist Pharmacy and Medicines Optimisation Team HPFT July 2017 1
More informationClass Update: Second Generation Antidepressant Medications. Dossier received: Yes
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationJoel V. Oberstar, M.D. 1
Diagnosis and Treatment of Depressive Disorders in Children and Adolescents Joel V. Oberstar, M.D. CEO & Chief Medical Officer Adjunct Assistant Professor of Psychiatry University of Minnesota Medical
More informationMedical Treatment of Problem Gambling. Donald W. Black, M.D. Roy J. and Lucille A. Carver College of Medicine Department of Psychiatry
Medical Treatment of Problem Gambling Donald W. Black, M.D. Roy J. and Lucille A. Carver College of Medicine Department of Psychiatry Disclosures Research Support: Forest Labs Nellie Ball Trust Fund National
More information